Product now contains 300mg per serving!
Take an active role maintaining your health, longer [1-3]. The key ingredient in TRU NIAGEN® is NIAGEN® nicotinamide riboside (NR)—a unique form of vitamin B3 clinically proven to increase nicotinamide adenine dinucleotide (NAD) [4-6], the critical catalyst that powers metabolism and helps maintain healthy cellular function.*
NAD has been shown to decline with age[7, 8] and metabolic stress[9-12]. It has also been shown to help support many aspects of healthy aging:*
- Increases cellular metabolism and energy production*[9, 13]
- Maintains healthy mitochondria*[9, 10, 13, 14]
- Promotes cellular repair*[9-11, 13, 14]
- Supports muscle function, including maintenance of muscle mass*[13, 15, 16]
- Maintains healthy cholesterol levels already within the normal range*
The key ingredient in TRU NIAGEN® has been rigorously tested using internationally accepted safety protocols and its safety is well documented. Niagen has twice been successfully reviewed under FDA's new dietary ingredient (NDI) notification program and has also been successfully notified to the FDA as generally recognized as safe (GRAS). Niagen is the first and only patented form of nicotinamide riboside to be reviewed by the FDA and granted these safety and dietary statuses.
- Rajman, L., K. Chwalek, and D.A. Sinclair, Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab, 2018. 27(3): p. 529-547.
- Verdin, E., NAD(+) in aging, metabolism, and neurodegeneration. Science, 2015. 350(6265): p. 1208-13.
- Yoshino, J., J.A. Baur, and S.I. Imai, NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab, 2018. 27(3): p. 513-528.
- Airhart, S.E., et al., An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One, 2017. 12(12): p. e0186459.
- Martens, C.R., et al., Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun, 2018. 9(1): p. 1286.
- Trammell, S.A., et al., Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun, 2016. 7: p. 12948.
- Massudi, H., et al., Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 2012. 7(7): p. e42357.
- Zhou, C.C., et al., Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol, 2016. 173(15): p. 2352-68.
- Canto, C., et al., The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab, 2012. 15(6): p. 838-47.
- Gariani, K., et al., Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology, 2016. 63(4): p. 1190-204.
- Wang, S., et al., Nicotinamide riboside attenuates alcohol induced liver injuries via activation of SirT1/PGC-1alpha/mitochondrial biosynthesis pathway. Redox Biol, 2018. 17: p. 89-98.
- Seyssel, K., et al., Regulation of energy metabolism and mitochondrial function in skeletal muscle during lipid overfeeding in healthy men. J Clin Endocrinol Metab, 2014. 99(7): p. E1254-62.
- Zhang, H., et al., NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science, 2016. 352(6292): p. 1436-43.
- Mouchiroud, L., et al., The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell, 2013. 154(2): p. 430-41.
- Frederick, D.W., et al., Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab, 2016. 24(2): p. 269-82.
- Gomes, A.P., et al., Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell, 2013. 155(7): p. 1624-38.
- Conze, D.B., J. Crespo-Barreto, and C.L. Kruger, Safety assessment of nicotinamide riboside, a form of vitamin B3. Hum Exp Toxicol, 2016.